Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mirtazapine in recurrent brief depression

M Stamenkovic1, L Pezawas, M de Zwaan

  • 1Department of General Psychiatry, University Hospital for Psychiatry, Vienna, Austria.

International Clinical Psychopharmacology
|February 13, 1999
PubMed
Summary

Recurrent brief depression (RBD) treatment is understudied. Mirtazapine showed promise in reducing the severity, duration, and frequency of depressive episodes in two patients with RBD.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for Light Pseudoscalar Bosons, Pair-Produced in Higgs Boson Decays in the Four-Electron Final State in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

First Evidence for Mixing-Induced CP Violation in B_{s}^{0}→J/ψϕ(1020) Decays in pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

Observation of Suppressed Charged-Particle Production in Ultrarelativistic Oxygen-Oxygen Collisions.

Physical review letters·2026
Same author

Measurement of D^{0} Meson Photoproduction in Ultraperipheral Heavy Ion Collisions.

Physical review letters·2026
Same author

Observation of tWZ Production at the CMS Experiment.

Physical review letters·2026
Same author

First Exclusive Reconstruction of the B^{*+}, B^{*0}, and B_{s}^{*0} Mesons and Precise Measurement of Their Masses.

Physical review letters·2026

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Recurrent brief depression (RBD) affects approximately 10% of the general population.
  • Current treatment data for RBD is limited, with selective serotonin reuptake inhibitors showing no significant advantage over placebo.

Observation:

  • Two patients diagnosed with RBD were treated with 30 mg of mirtazapine daily for 4 months.
  • Patients meticulously documented their major depressive symptoms using a diary.

Findings:

  • Mirtazapine treatment resulted in a significant reduction in the severity, duration, and frequency of brief depressive episodes.
  • The dual mechanism of action of mirtazapine, enhancing both serotonergic and noradrenergic neurotransmission, may be key to its efficacy in RBD.

Implications:

Related Experiment Videos

  • Mirtazapine presents a potential therapeutic option for managing Recurrent Brief Depression.
  • Further controlled studies are necessary to validate these preliminary findings and establish mirtazapine's role in RBD treatment.